Role of dipeptidyl peptidase-4 inhibitors in the prevention and treatment of ischemic stroke
10.3760/cma.j.issn.1673-4165.2024.05.010
- VernacularTitle:二肽基肽酶-4抑制剂在缺血性卒中预防和治疗中的作用
- Author:
Jingxuan ZHANG
1
;
Xuan HE
;
Dujuan SHA
Author Information
1. 南京中医药大学鼓楼临床医学院全科医学科，南京 210008
- Keywords:
Stroke;
Brain ischemia;
Dipeptidyl peptidase 4;
Dipeptidyl-peptidase IV inhibitors;
Diabetes mellitus, type 2;
Neuroprotective agents
- From:
International Journal of Cerebrovascular Diseases
2024;32(5):369-373
- CountryChina
- Language:Chinese
-
Abstract:
Diabetes is an important risk factor for ischemic stroke, and stress hyperglycemia after ischemic stroke will aggravate ischemic brain damage. Dipeptidyl peptidase-4 (DPP-4) inhibitors, as newly developed hypoglycemic drugs in recent years, have become one of the important research directions of type 2 diabetes drugs. Although the existing clinical trial data have not clearly confirmed the effectiveness of DPP-4 inhibitors in preventing ischemic stroke in patients with diabetes, animal model studies have shown that DPP-4 inhibitors can exert protective effects during ischemic brain injury through mechanisms such as anti-inflammatory, anti-apoptotic and promoting neurogenesis and angiogenesis. This article reviews the role and possible mechanisms of DPP-4 inhibitors in the prevention and treatment of ischemic stroke.
